Log in
Providing a VOICE for Wisconsin's MULTIDISCIPLINARY CANCER CARE TEAMs and the PATIENTS THEY SERVE since 1991
Join/Renew
About
About Us
Executive Office
Leadership
Community (Members Only)
Meetings & Education
Upcoming Events
Poster Presentations
Articles and Podcasts
Advocacy
Access to Care Policy Project
Advocacy Engagement Pilot
Advocacy Support
Patient Advocacy Organizations
White Bagging
Resources
State & Federal Resources
Financial Advocacy & Patient Assistance
Find A Clinical Trial
Off-Label Use Literature
Jobs
Latest News
Educational Resources
Industry
Corporate Members
Exhibitor Information
Industry News
Industry News
FDA Approves Cemiplimab-rwlc Monotherapy for Advanced NSCLC
On Febr
uary 22, 2021, the U.S. Food and Drug Administration (FDA) approved cemiplimab-rwlc for the first-line treatment of advanced non-small cell lung cancer (NSCLC) in patients whose tumors have high PD-L1 expression (tumor proportion score ≥50%), as determined by an FDA-approved test. Patients must either have metastatic or locally advanced tumors that are not candidates for surgical resection or definitive chemoradiation, and the tumors must not have EGFR, ALK, or ROS1 aberrations.
Read the
FDA announcement
.
Read the
Sanofi
announcement.
Posted 2/22/2021